 n the selection of performance measures, the strategic objectives , and short -term and long -term business 
priorities for 202 4 have been considered . The criteria are the same for the CEO , management and key people . 
The variable cash remuneration may amount to a maximum of 40 percent of the annual fixed cash salary for 
the CEO. Further variable cash remuneration may be awarded in extraordinary circumstances. Such 
remuneration may not exceed an amount corresponding to 50 percent of the fixed annual cash salary and may 
not be paid more than once per year for each individual. 
Table 4 - Performance of the CEO in the reported financial year: variable cash remuneration 
Name (position) Description of the criteria 
related to the 
remuneration component Relative weighting of the 
performance criteria a) Measured performance and 
b) Actual award/ remuneration outcome 
Ahmed Mousa (CEO)1 Financial criteria, 
Preclinical and clinical 
studies 
 100% a) 90%2 
b) 1,146 KSEK 
 Individual  6 KSEK 
 Individual b onus related to 
financing activities 328 KSEK 
 Sign -on bonus (2nd and final 
bonus payment, 6 months 
after start of employment) 247 KSEK 
Total 1,721 KSEK 
 
1. No additional individual variable cash remuneration has been paid to the CEO during 202 4. 
2. Of the established goals, 70% were measur ed by the end of the year, of which 90% were achieved. 
Comparative information on the change of remuneration and company performance 
Table 5 â€“ Change of remuneration and company performance over the last five reported financial years 
(RFY) (KSEK) 
 RFY 2020 RFY 2021 RFY 2022 RFY 2023 RFY 2024 
CEO remuneration1 2,296 6,881 
Former CEO remuneration1 4,016 3,768 4,466 3,926 
Group operating profit (loss) (149,538) (294,818) (290,725) (321,506) (194,189 ) 
Average remuneration on a full -time equivalent 
basis of employees2 of the group company 1,869 1,709 2,290 2,469 2,591 
 
1. Including pension, variable cash remuneration and holiday pay. Excluding social fees and 